Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Jul 5;19(4):501–511. doi: 10.1007/s10456-016-9522-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2016

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

PMC Copyright notice

Fig. 7 — Celecoxib and octreotide synergistically inhibited angiogenesis via p-ERK–HIF-1α–VEGF. Cele + Oct or AZD could significantly reduce the migration rate (a, c) and tube formation (b, d) compared with DMSO-treated HUVEC cells. The VEGF mRNA (e) and protein (f, g) p-ERK (f, h), HIF-1α protein (h) determined by immunofluorescence, and qRT-PCR and Western blot were also abolished by Cele, Oct, Cele + Oct or AZD. ChIP assay was to determine HIF-1α binding to VEGF promoter region (i). AZD, MEK inhibitor AZD6244. ^# p < 0.05 versus DMSO. *p < 0.05 versus Cele + Oct